MyFinsight
Home
Blog
About
Keros Therapeutics, Inc. (KROS)
Keros Therapeutics, Inc. (KROS)
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$23,891K
Free Cash flow
-$20,576K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Stock-based compensation expense
Accrued expenses and other curre...
Non-cash lease expense
Others
Negative Cash Flow Breakdown
Payment of direct expenses assoc...
Right-of-use assets and operatin...
Prepaid expenses and other curre...
Purchase of property and equipme...
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-28,710
-23,708
-23,461
-7,280
Depreciation expense
402
403
400
395
Gain on disposal of fixed asset
0
-
-1
0
Stock-based compensation expense
5,377
6,199
7,305
3,986
Non-cash lease expense
652
636
622
609
Accounts receivable
-400
-3,167
75
-12,324
Prepaid expenses and other current assets
497
-15,672
-141
-4,434
Current income tax receivable
-
-
2,250
-
Other assets
0
0
0
0
Accounts payable
323
-108
-697
-2,955
Right-of-use assets and operating lease liabilities
587
572
546
525
Deferred revenue
0
-155
-
-770
Current tax liability
0
-4,147
-
-2,174
Accrued expenses and other current liabilities
2,219
-5,218
-4,430
-4,795
Net cash provided by (used in) operating activities
-20,421
-3,529
-27,292
3,249
Purchase of property and equipment
155
73
134
132
Net cash used in investing activities
-155
-73
-134
-132
Proceeds from issuance of common stock-Secondary Offering
-
-
0
0
Payment of issuance costs
-
-
0
0
Proceeds from issuance of common stock-At The Market Offering
-
-
0
0
Payment of issuance costs associated with issuance of common stock under the atm agreement-At The Market Offering
-
-
-
0
Payment of issuance costs associated with issuance of common stock under the atm agreement
-
-
0
-
Proceeds from issuance of common stock under the employee stock purchase plan
-
-
0
138
Repurchase of treasury stock
-
-
375,000
-
Payment of direct expenses associated with the treasury stock repurchase
3,338
2,323
3,897
-
Short-swing profit settlement
-
-
139
-
Proceeds from exercise of stock options
23
7
127
2
Net cash provided by (used in) financing activities
-3,315
-2,316
-378,631
140
Net increase (decrease) in cash, cash equivalents and restricted cash
-23,891
-5,918
-406,057
3,257
Cash, cash equivalents and restricted cash at beginning of period
282,946
288,864
694,921
561,380
Cash, cash equivalents and restricted cash at end of period
259,055
282,946
288,864
694,921
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net increase
(decrease) in cash, cash...
-$23,891K
(-118.34%↓ Y/Y)
Stock-based compensation
expense
$5,377K
(-69.11%↓ Y/Y)
Accrued expenses and
other current...
$2,219K
(344.92%↑ Y/Y)
Non-cash lease expense
$652K
(-44.70%↓ Y/Y)
Depreciation expense
$402K
(-43.70%↓ Y/Y)
Accounts receivable
-$400K
(-103.06%↓ Y/Y)
Accounts payable
$323K
(-50.38%↓ Y/Y)
Proceeds from exercise of
stock options
$23K
(9.52%↑ Y/Y)
Net cash provided by
(used in) operating...
-$20,421K
(-115.52%↓ Y/Y)
Net cash provided by
(used in) financing...
-$3,315K
(-15885.71%↓ Y/Y)
Net cash used in
investing activities
-$155K
(87.94%↑ Y/Y)
Canceled cashflow
$9,373K
Canceled cashflow
$23K
Net income (loss)
-$28,710K
(-124.38%↓ Y/Y)
Payment of direct
expenses associated with...
$3,338K
Purchase of property and
equipment
$155K
(-87.94%↓ Y/Y)
Right-of-use assets and
operating lease...
$587K
(-35.28%↓ Y/Y)
Prepaid expenses and
other current assets
$497K
(-10.77%↓ Y/Y)
Buy us a coffee